INSILICO MEDICINE IP LIMITED

INSILICO MEDICINE IP LIMITED has been granted 36 US utility patents between 2020 and 2025, placing INSILICO MEDICINE IP LIMITED at rank #8,831 across all assignees tracked by PlainPatent. This portfolio spans 16 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.2 claims per patent with primary concentration in C07D (HETEROCYCLIC COMPOUNDS). As a Foreign Corporation, INSILICO MEDICINE IP LIMITED is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 59.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 36 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. INSILICO MEDICINE IP LIMITED's 21.2 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 16 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark INSILICO MEDICINE IP LIMITED against peers pursuing similar technology classes.